Targeting chordoma via an isocitrate dehydrogenase-1-dependent susceptibility to redox metabolism
Acta Neuropathologica · 23.07.2026 · 152 (1)
DOI: 10.1007/s00401-026-03048-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neuropathologica, online erschienen am 23.07.2026. Verfasst von Matthew Pun und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Laboratory of Brain Tumor Metabolism and Epigenetics, University of Michigan, Ann Arbor, MI, USA. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Chordoma. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Chordomas are rare cancers that arise along the axial skeleton. Alterations in metabolism are a hallmark of cancer, and we sought to identify metabolic vulnerabilities in chordoma. We discovered that the tricarboxylic acid (TCA)-related enzyme isocitrate dehydrogenase-1 ( IDH1 ) was expressed highly in bulk and single-cell patient-derived chordomas and was associated with worse survival outcomes. IDH1 catalyzes the conversion of isocitrate and nicotinamide adenine dinucleotide phosphate (NADP+) to alpha-ketoglutarate (⍺-KG) and NADPH. This critical reaction influences TCA cycle metabolism, regulates epigenetic pathways, and affects redox balance. Both IDH1 knockdown and treatment with an inhibitor targeting IDH1 were toxic to chordoma cells. An integrated analysis of the transcriptomic, chromatin, and metabolomic responses on IDH1 inhibition converged on deregulated glutathione metabolism. IDH1 inhibition was associated with increased expression and enrichment of activating H3K27ac at NRF2 (nuclear factor erythroid 2-related factor 2) signature genes including those in the glutathione biosynthetic pathway. This was accompanied by reduction of both NADPH/NADP+ and reduced/oxidized glutathione (GSH/GSSG) ratios. Importantly, IDH1 inhibitor-driven toxicity was rescued via media supplementation with the antioxidant N -acetylcysteine, suggesting that IDH1 inhibition in chordomas creates a redox-dependent metabolic vulnerability. Finally, IDH1 inhibitor treatment reduced tumor growth in two independent chordoma mouse xenograft models. Our findings suggest a potential therapeutic avenue for further exploration in chordoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Laboratory of Brain Tumor Metabolism and Epigenetics, University of Michigan, Ann Arbor, MI, USA.
- Department of Pediatrics, Michigan Medicine, Ann Arbor, MI, USA.
- Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
- Department of Pathology, Children's Hospital of Los Angeles, Los Angeles, CA, 90027, USA.
- Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, USA.
- Department of Otolaryngology/Head Neck Surgery, University of Michigan School of Medicine, Ann Arbor, MI, 48109-5616, USA.
Förderung
- NCI NIH HHS
- NINDS NIH HHS
Zitieren
APA
Pun, M., Deogharkar, A., Natarajan, S. K., Nuechterlein, N., Tian, W., Ji, S., Young, E., Yang, F., Hawes, D., Andren, A. C., Owen, J. H., Rau, S., Su, F., Cao, X., Parolia, A., Prince, M., Fry, J., Gardner, P. A., Yang, R., …, & Venneti, S. (2026). Targeting chordoma via an isocitrate dehydrogenase-1-dependent susceptibility to redox metabolism. Acta Neuropathologica, 152(1). https://doi.org/10.1007/s00401-026-03048-9
Vancouver
Pun M, Deogharkar A, Natarajan SK, Nuechterlein N, Tian W, Ji S, et al. Targeting chordoma via an isocitrate dehydrogenase-1-dependent susceptibility to redox metabolism. Acta Neuropathologica. 2026;152(1). doi:10.1007/s00401-026-03048-9
BibTeX
@article{Pun2026,
author = {Pun, Matthew and Deogharkar, Akash and Natarajan, Siva Kumar and Nuechterlein, Nicholas and Tian, Wentao and Ji, Sunjong and Young, Eleanor and Yang, Fusheng and Hawes, Debra and Andren, Anthony C and Owen, John Henry and Rau, Sagar and Su, Fengyun and Cao, Xuhong and Parolia, Abhijit and Prince, Mark and Fry, Joshua and Gardner, Paul A and Yang, Rendong and Judkins, Alexander R and Koschmann, Carl J and Venteicher, Andrew S and Lyssiotis, Costas A and Chinnaiyan, Arul M and Venneti, Sriram},
title = {Targeting chordoma via an isocitrate dehydrogenase-1-dependent susceptibility to redox metabolism},
journal = {Acta Neuropathologica},
year = {2026},
volume = {152},
number = {1},
doi = {10.1007/s00401-026-03048-9}
}
EUVIMED